190 related articles for article (PubMed ID: 22609829)
1. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.
Dargart JL; Fish K; Gordon LI; Longnecker R; Cen O
Antiviral Res; 2012 Jul; 95(1):49-56. PubMed ID: 22609829
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
Cen O; Longnecker R
Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
[TBL] [Abstract][Full Text] [Related]
3. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
[TBL] [Abstract][Full Text] [Related]
4. Two Pathways of p27
Sora RP; Ikeda M; Longnecker R
mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
[TBL] [Abstract][Full Text] [Related]
5. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
Ikeda M; Hayes CK; Schaller SJ; Longnecker R
Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
Bieging KT; Amick AC; Longnecker R
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.
Incrocci R; Hussain S; Stone A; Bieging K; Alt LA; Fay MJ; Swanson-Mungerson M
Cell Immunol; 2015 Oct; 297(2):108-19. PubMed ID: 26255694
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease.
Cooper L; Longnecker R
Antiviral Res; 2002 Dec; 56(3):219-31. PubMed ID: 12406506
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
Fish K; Chen J; Longnecker R
Blood; 2014 Jan; 123(4):530-40. PubMed ID: 24174629
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn.
Rovedo M; Longnecker R
J Virol; 2008 Sep; 82(17):8520-8. PubMed ID: 18579586
[TBL] [Abstract][Full Text] [Related]
11. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.
Swart R; Ruf IK; Sample J; Longnecker R
J Virol; 2000 Nov; 74(22):10838-45. PubMed ID: 11044134
[TBL] [Abstract][Full Text] [Related]
12. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
13. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
Bultema R; Longnecker R; Swanson-Mungerson M
Oncogene; 2009 Mar; 28(11):1471-6. PubMed ID: 19182823
[TBL] [Abstract][Full Text] [Related]
15. Mouse model for acute Epstein-Barr virus infection.
Wirtz T; Weber T; Kracker S; Sommermann T; Rajewsky K; Yasuda T
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13821-13826. PubMed ID: 27856754
[TBL] [Abstract][Full Text] [Related]
16. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
Pang MF; Lin KW; Peh SC
Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
[TBL] [Abstract][Full Text] [Related]
17. Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.
Fish K; Comoglio F; Shaffer AL; Ji Y; Pan KT; Scheich S; Oellerich A; Doebele C; Ikeda M; Schaller SJ; Nguyen H; Muppidi J; Wright GW; Urlaub H; Serve H; Staudt LM; Longnecker R; Oellerich T
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26318-26327. PubMed ID: 33020271
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma.
Portis T; Dyck P; Longnecker R
Blood; 2003 Dec; 102(12):4166-78. PubMed ID: 12907455
[TBL] [Abstract][Full Text] [Related]
19. K1 and K15 of Kaposi's Sarcoma-Associated Herpesvirus Are Partial Functional Homologues of Latent Membrane Protein 2A of Epstein-Barr Virus.
Steinbrück L; Gustems M; Medele S; Schulz TF; Lutter D; Hammerschmidt W
J Virol; 2015 Jul; 89(14):7248-61. PubMed ID: 25948739
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
